Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing antibody-based therapies for rare bleeding and thrombotic disorders. The company pioneers preventative treatments and functional cures targeting conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease, where current options often fall short in providing effective prophylaxis or long-term management. Hemab's targeted therapies leverage advances in biology and drug modalities to address blood coagulation challenges, aiming to reduce lifelong disease burdens for patients. Operating within the pharmaceuticals and biotech sector, it builds a franchise around select coagulation disorders by uniting expertise in clotting science, patient care, and drug development. Founded in 2020 and headquartered in Cambridge, Massachusetts, Hemab Therapeutics Holdings, Inc. plays a key role in advancing novel solutions for underserved areas of hematology, contributing to improved disease management in rare bleeding disorders.
$51.74
+$1.87 (+3.75%)
EOD Aug 11, 2026
ROIC dropped from -2307.40% to -3761.90%, capital efficiency is deteriorating. Negative free cash flow of -$61M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$64M
▼ -31.2% YoY
Op. Margin
—
ROIC
-3761.90%
▼ -1454.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$61M
▼ -34.0% YoY
Op. Cash Flow (TTM)
-$61M
▼ -34.8% YoY
Net Debt
-$184M
Net Cash Position
Cash & Equiv.
$185M
Continue Research
Hemab Therapeutics Holdings (COAG)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hemab Therapeutics Holdings scores 18/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Hemab Therapeutics Holdings scores 18 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -3,761.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh COAG's valuation and scores 18/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.